ClinicalTrials.gg
CompletedNCT01355081Updated Nov 11, 2014Results posted

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine and Placebo in Major Depressive Disorder, sponsored by Takeda. Completed at 32 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-11-11.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
29th of 54
366 · median 413
Started
2011
with 4 others
Phase 3
31 of 54
1 open now
Registered
18th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 29th largest by enrollment, is one of 5 that started in 2011, is one of 31 in phase 3, and was the 18th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Vortioxetine (Lu AA21004), once daily (QD), in Japanese participants with major depressive disorder.

The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Lu AA21004, once daily (QD), in Japanese participants with major depressive disorder.

Read the detailed description

Lu AA21004 was discovered by H. Lundbeck A/S, and is under co-development by H. Lundbeck A/S and Takeda for the treatment of major depressive disorder and general anxiety disorder. Major depressive disorder (MDD) is a chronic, recurring disease with considerable morbidity in the general population. The estimated lifetime prevalence of major depression in the adult population is 5 to 25%, with approximately 2-fold higher prevalence in women than in men. The hallmark of the disease is a depressed mood, with additional symptoms including sleep disturbances, psychomotor agitation or retardation, sexual dysfunction, weight loss, concentration difficulties and delusional ideas. In addition to direct ill effects, MDD causes suicide or job loss and exerts indirect influence on social economy. This study will assess the efficacy and the safety of Lu AA21004. This study consists of a 1-week screening period, an 8-week double-blind treatment period, 4-week safety follow-up.The duration of the study is 13 weeks in total. Blood samples will be collected from participants, and a safety follow-up contact (visit or phone call) will be made 4 weeks after completion of the 8-week double-blind treatment period. Subjects who complete the 8-week double-blind treatment period can successively enter a long-term extension study (Lu AA21004/OCT-001; NCT01395147; hereinafter, OCT-001), if they meet all inclusion criteria and none of exclusion criteria of the OCT-001 study and are willing to participate in the OCT-001 study. Subjects who will enter the OCT-001 will not be requested to safety follow-up after completion of the 8-week double-blind treatment period.

Lu AA21004 was discovered by H. Lundbeck A/S, and is under co-development by H. Lundbeck A/S and Takeda for the treatment of major depressive disorder and general anxiety disorder.

Major depressive disorder (MDD) is a chronic, recurring disease with considerable morbidity in the general population. The estimated lifetime prevalence of major depression in the adult population is 5 to 25%, with approximately 2-fold higher prevalence in women than in men. The hallmark of the disease is a depressed mood, with additional symptoms including sleep disturbances, psychomotor agitation or retardation, sexual dysfunction, weight loss, concentration difficulties and delusional ideas. In addition to direct ill effects, MDD causes suicide or job loss and exerts indirect influence on social economy.

This study will assess the efficacy and the safety of Lu AA21004. This study consists of a 1-week screening period, an 8-week double-blind treatment period, 4-week s safety follow-up.The duration of the study is 13 weeks in total. Blood samples will be collected from participants, and a safety follow-up contact (visit or phone call) will be made 4 weeks after completion of the 8-week double-blind treatment period.

Subjects who complete the 8-week double-blind treatment period can successively enter a long-term extension study (Lu AA21004/OCT-001; NCT01395147; hereinafter, OCT-001), if they meet all inclusion criteria and none of exclusion criteria of the OCT-001 study and are willing to participate in the OCT-001 study.

Subjects who will enter the OCT-001 will not be requested to safety follow-up after completion of the 8-week double-blind treatment period.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject suffers from Major Depressive Disorder (MDD) as the primary diagnosis according to the , 4th Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.2x and 296.3x).
  2. The reported duration of the current major depressive episode is at least 3 months at the Screening Visit.
  3. The subject has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Screening and Baseline Visits.
  4. The subject has a Clinical Global Impression Scale-Severity (CGI-S) score ≥4 at the Screening and Baseline Visits

Exclusion criteria

Exclusion Criteria:

  1. The subject has one or more of the following conditions:

    • Any current psychiatric disorder other than MDD as defined in the . A subject who exhibits symptoms of anxiety is eligible unless the subject fulfills the diagnostic criteria for a current anxiety disorder per DSM-IV-TR.
    • Current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Current diagnosis or history of any substance-related disorder (except nicotine and caffeine-related disorders) as defined in the DSM-IV-TR.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, etc.).
    • Any DSM-IV-TR axis II disorder that might compromise the study.
  2. The current depressive symptoms of the subject are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
  3. The subject is at significant risk of suicide or has a score ≥5 on Item 10 (suicidal thoughts) of the MADRS at the Screening and Baseline Visit, or has attempted suicide within 6 months prior to the Screening Visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Vortioxetine 5 mg

    Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.

    Drug: Vortioxetine

  • Placebo comparator
    Placebo

    Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.

    Drug: Placebo

Interventions

  • Vortioxetine tablets

    Also known as: Lu AA21004, BRINTELLIX

  • DrugPlacebo

    Vortioxetine placebo

    Also known as: Vortioxetine placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment

    MADRS is a 10-item clinician rated scale that measures overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates that symptoms have improved. An analysis of covariance (ANCOVA) model was used with change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Percentage of Patients With MADRS Response After 8 Weeks of Treatment

    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Response is defined as a ≥50% decrease in the MADRS Total Score from Baseline.

    Time frame: Baseline, Week 8

  2. Percentage of Patients With MADRS Remission After 8 Weeks of Treatment

    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Remission is defined as a MADRS Total Score ≤10.

    Time frame: Week 8

  3. Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment

    The HAM-D17 is a 17-item rating scale that assesses depressed mood, agitation and somatic symptoms of depression, rated on a 5-point scale from 0 (absent) to 4 (very severe) with a total score range from 0 to 52. Higher scores indicate greater severity of depression symptoms. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the baseline HAM-D17 score as a covariate.

    Time frame: Baseline, Week 8

  4. Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment

    The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. ANCOVA model was used with treatment as a fixed effect and the baseline CGI-Severity (CGI-S) score as a covariate.

    Time frame: Baseline, Week 8

  5. Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment

    The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the Baseline SDS total score as a covariate.

    Time frame: Baseline, Week 8

07

Results

Posted Nov 11, 2014

Participant flow

Participants took part in the study at 32 investigative sites throughout Japan from 13 May 2011 to 21 December 2012.

Participant flow — Overall Study
MilestoneVortioxetine 5 mgVortioxetine 10 mgPlacebo
Started119123124
Completed112113113
Not completed71011
Withdrew: Pretreatment event or adverse event346
Withdrew: Major protocol deviation010
Withdrew: Lost to follow-up001
Withdrew: Withdrawal of consent233
Withdrew: Lack of efficacy211
Withdrew: Non compliance with study medication010

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment

MADRS is a 10-item clinician rated scale that measures overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates that symptoms have improved. An analysis of covariance (ANCOVA) model was used with change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment
scores on a scaleVortioxetine 5 mgVortioxetine 10 mgPlacebo
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment-15.84 ± 0.885-14.85 ± 0.874-13.81 ± 0.870
Statistical analysis
  • Vortioxetine 5 mg vs Placebo · ANCOVA · p = 0.1031 · Least square means difference: -2.03 · 95% CI -4.467 to 0.413Change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.
  • Vortioxetine 10 mg vs Placebo · ANCOVA · p = 0.4008 · Least square mean difference: -1.04 · 95% CI -3.461 to 1.387Change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.
SecondaryPercentage of Patients With MADRS Response After 8 Weeks of Treatment

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Response is defined as a ≥50% decrease in the MADRS Total Score from Baseline.

Time frame:
Baseline, Week 8
Reported as:
Number · percentage of participants
Percentage of Patients With MADRS Response After 8 Weeks of Treatment
percentage of participantsVortioxetine 5 mgVortioxetine 10 mgPlacebo
Percentage of Patients With MADRS Response After 8 Weeks of Treatment51.345.939.8
SecondaryPercentage of Patients With MADRS Remission After 8 Weeks of Treatment

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Remission is defined as a MADRS Total Score ≤10.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Patients With MADRS Remission After 8 Weeks of Treatment
percentage of participantsVortioxetine 5 mgVortioxetine 10 mgPlacebo
Percentage of Patients With MADRS Remission After 8 Weeks of Treatment29.428.722.0
SecondaryChange From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment

The HAM-D17 is a 17-item rating scale that assesses depressed mood, agitation and somatic symptoms of depression, rated on a 5-point scale from 0 (absent) to 4 (very severe) with a total score range from 0 to 52. Higher scores indicate greater severity of depression symptoms. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the baseline HAM-D17 score as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment
scores on a scaleVortioxetine 5 mgVortioxetine 10 mgPlacebo
Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment-9.56 ± 0.586-8.54 ± 0.580-8.40 ± 0.578
SecondaryClinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment

The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. ANCOVA model was used with treatment as a fixed effect and the baseline CGI-Severity (CGI-S) score as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment
scores on a scaleVortioxetine 5 mgVortioxetine 10 mgPlacebo
Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment2.44 ± 0.1002.57 ± 0.0992.66 ± 0.099
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment

The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the Baseline SDS total score as a covariate.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment
scores on a scaleVortioxetine 5 mgVortioxetine 10 mgPlacebo
Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment-5.01 ± 0.510-4.02 ± 0.506-2.91 ± 0.504

Adverse events

Collected over 8-week double blind treatment period and 4-week follow-up safety period, or up to 4 weeks after withdrawal visit, excluding those who enrolled in the long-term extension study (Up to 12 Weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine 5 mg—1/119 (0.8%)80/119 (67.2%)
Vortioxetine 10 mg—1/122 (0.8%)93/122 (76.2%)
Placebo—1/124 (0.8%)78/124 (62.9%)
Most frequent serious events
Most frequent serious events
EventVortioxetine 5 mgVortioxetine 10 mgPlacebo
Brain contusionInjury, poisoning and procedural complications1/1190/1220/124
Road traffic accidentInjury, poisoning and procedural complications1/1190/1220/124
Cerebral haematomaNervous system disorders1/1190/1220/124
Subarachnoid haemorrhageNervous system disorders1/1190/1220/124
Suicidal behaviourPsychiatric disorders0/1191/1220/124
Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1190/1221/124
Most frequent other events
Showing 10 of 136
Most frequent other events
EventVortioxetine 5 mgVortioxetine 10 mgPlacebo
NauseaGastrointestinal disorders20/11935/1229/124
NasopharyngitisInfections and infestations24/11917/12221/124
DiarrhoeaGastrointestinal disorders10/11913/12210/124
SomnolenceNervous system disorders7/11912/1229/124
HeadacheNervous system disorders10/1196/1228/124
Suicidal ideationPsychiatric disorders1/1198/1222/124
Blood creatine phosphokinase increasedInvestigations5/1191/1225/124
ConstipationGastrointestinal disorders2/1195/1224/124
ThirstGeneral disorders3/1195/1223/124
DizzinessNervous system disorders2/1195/1222/124

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Mean38.8 ± 10.8538.8 ± 10.9937.6 ± 10.6738.4 ± 10.83
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Female505467171
Male696957195
Region of Enrollment
Region of Enrollment(participants)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Japan119123124366
Height
Height(cm)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Mean165.7 ± 8.45165.6 ± 8.51163.9 ± 8.46165.1 ± 8.49
Weight
Weight(kg)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Mean62.18 ± 11.35762.11 ± 15.88360.86 ± 12.69061.71 ± 13.441
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Mean22.59 ± 3.36622.42 ± 4.30622.57 ± 4.01622.53 ± 3.911
Cytochrome p450 (CYP)2D6 Phenotype
Cytochrome p450 (CYP)2D6 Phenotype(participants)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Ultra-rapid Metabolizer (UM)1124
Extensive Metabolizer (EM)919796284
Intermediate Metabolizer (IM)25202166
Poor Metabolizer (PM)0101
Unknown24511
Smoking Classification
Smoking Classification(participants)Vortioxetine 5 mgVortioxetine 10 mgPlaceboTotal
Current smoker394140120
Ex-smoker26242474
Never Smoked545860172

7 further baseline measures are reported on the registry.

08

Study locations

32 sites
  • Inzai-shi, Chiba, Japan
  • Noda-City, Chiba, Japan
  • Fukuoka-city, Fukuoka, Japan
  • Kitakyushu-shi, Fukuoka, Japan
  • Annaka-shi, Gunma, Japan
  • Fujioka-shi, Gunma, Japan
  • Takasaki-shi, Gunma, Japan
  • Hatsukaichi-shi, Hiroshima, Japan
  • Hiroshima-shi, Hiroshima, Japan
  • Sapporo-Shi, Hokkaido, Japan
  • Amagasaki-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Fujisawa-shi, Kanagawa, Japan
  • Kawasaki-shi, Kanagawa, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Osaka-shi, Kita-ku, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Kurashiki-shi, Okayama, Japan
  • Osaka-shi, Osaka, Japan
  • Fukaya-shi, Saitama, Japan
  • Saitama-city, Saitama, Japan
  • Utsunomiya-shi, Tochigi, Japan
  • Anan-shi, Tokushima, Japan
  • Tokushisma-shi, Tokushima, Japan
  • Hachioji-shi, Tokyo, Japan
  • Katsushika-ku, Tokyo, Japan
  • Musashino-shi, Tokyo, Japan
  • Nanyo-shi, Yamagata, Japan
  • Ibaraki, Japan
  • Tokyo, Japan
09

References and documents

Publications

  • Inoue T, Nishimura A, Sasai K, Kitagawa T. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial. Psychiatry Clin Neurosci. 2018 Feb;72(2):103-115. doi: 10.1111/pcn.12623. Epub 2017 Dec 27. PubMed 29160598 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2011
First posted
May 17, 2011
Start
May 2011
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Nov 11, 2014
Last update
Nov 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01355081
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 17, 2011
Start date
May 2011
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Nov 11, 2014
Last update
Nov 11, 2014

Study contacts

Senior Manager
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion